HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

Area of Science:

• Epigenetics and molecular biology
• Cancer research
• Cellular biology

Background:

• Epigenetic modifications, such as deacetylation, are key regulators in cancer development.
• Histone deacetylase 6 (HDAC6) is implicated in carcinogenesis through diverse cellular functions.
• While HDAC6 inhibitors show promise in inducing mitotic arrest, the underlying mechanisms require further elucidation.

Purpose of the Study:

• To review and synthesize information on HDAC6-associated proteins critical for mitosis.
• To discuss the current landscape of therapeutic agents targeting HDAC6.
• To provide insights into the role of HDAC6 in tumorigenesis and cell division.

Main Methods:

• Literature review and synthesis of existing research on HDAC6.
• Analysis of proteins interacting with HDAC6 during mitosis.
• Review of preclinical and clinical studies on HDAC6 inhibitors.

Main Results:

• HDAC6 interacts with numerous proteins that play vital roles in mitotic progression.
• Dysregulation of HDAC6 contributes to uncontrolled cell proliferation and cancer.
• HDAC6 inhibitors have demonstrated potential in halting cancer cell division.

Conclusions:

• HDAC6 is a significant target in cancer therapy due to its role in mitosis and tumorigenesis.
• Understanding HDAC6-associated proteins can reveal novel therapeutic strategies.
• Further development of HDAC6-targeting agents holds promise for cancer treatment.